Ignite Creation Date:
2025-12-24 @ 2:54 PM
Ignite Modification Date:
2025-12-26 @ 12:39 PM
Study NCT ID:
NCT02470559
Status:
WITHDRAWN
Last Update Posted:
2016-02-17
First Post:
2015-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Sponsor:
Barbara Ann Karmanos Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06
Start Date Type:
None
Primary Completion Date:
2017-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2017-02
Completion Date Type:
ESTIMATED
First Submit Date:
2015-06-10
First Submit QC Date:
None
Study First Post Date:
2015-06-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-02-15
Last Update Post Date:
2016-02-17
Last Update Post Date Type:
ESTIMATED